Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”

por Munafo, Alain, Krebs-Brown, Axel, Gaikwad, Sumedh, Urgatz, Bogumila, Castello-Bridoux, Claire
Publicado 2019

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

por Krebs-Brown, Axel, Munafo, Alain, Gaikwad, Sumedh, Urgatz, Bogumila, Castello-Bridoux, Claire
Publicado 2019

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunte...

por Schnaars, Yvonne, Gaikwad, Sumedh, Gottwald-Hostalek, Ulrike, Klingberg, Ulrike, Vadla, Hari Kiran Chary, Prathap, Vamshi Ramana
Publicado 2022

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

por Schnaars, Yvonne, Gaikwad, Sumedh, Gottwald-Hostalek, Ulrike, Uhl, Wolfgang, Ribot, Olga, Varanasi, Kanthikiran V. S., Rodríguez, Laura, Torrejón, Javier, Gómez, Luis
Publicado 2022